The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Year to date metric has recorded a loss of -23.50%.However, over the last six months, we can see a stronger performance of -19.50%. Over the last 30 days, the price of RXRX has fallen by 9.16%. And in the last five days, it has fallen by -8.79%.
Recursion Pharmaceuticals Inc’s market performance has been unstable in recent times. The company’s stock hit a 1-year high of $15.74 on 02/27/24 and a low of $5.60 for the same time frame on 11/22/24.
52-week price history of RXRX Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Recursion Pharmaceuticals Inc’s current trading price is -52.08% away from its 52-week high, while its distance from the 52-week low is 34.70%. The stock’s price range during this period has varied between$5.60 and $15.74. The Recursion Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 11.25 million for the day, a figure considerably higher than their average daily volume of 8.18 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Recursion Pharmaceuticals Inc (RXRX) has experienced a quarterly rise of 11.58% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.92B.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 6.80, with a change in price of -0.58. Similarly, Recursion Pharmaceuticals Inc recorded 7,095,674 in trading volume during the last 100 days, posting a change of -7.20%.
RXRX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for RXRX stands at 0.17. Similarly, the long-term debt-to-equity ratio is also 0.14.
RXRX Stock Stochastic Average
As of today, Recursion Pharmaceuticals Inc’s raw stochastic average for the last 50 days stands at 47.34%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 47.34%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 38.82% and 40.82%, respectively.
